Literature DB >> 15273454

Doppler evaluation of the descending aorta in patients with hypertrophic cardiomyopathy: potential for assessing the functional significance of outflow tract gradients and for optimizing pacemaker function.

Steven Mickelsen1, Murali Bathina, Pamela Hsu, Joanna Holmes, Fred M Kusumoto.   

Abstract

UNLABELLED: We evaluated whether analysis of aortic flow could be useful for determining the functional significance of left ventricular outflow gradients and for optimizing pacing therapy in patients with hypertrophic cardiomyopathy (HOCM).
METHODS: Doppler echocardiography was performed in 32 patients with HOCM. Eleven patients with pacemakers (PPM) also underwent treadmill and quality-of-life (QOL) testing in a randomized crossover trial (1 month of backup pacing (AAI at 30 beats per minute), 1 month with an atrioventricular interval (AVI) of 30 ms (DDD30), and 1 month with an "optimized" AVI (DDDop) that maximized the descending aortic Doppler velocity time integral.
RESULTS: Patients with HOCM displayed a notch in the aortic Doppler flow profile. The location of the notch in systole corresponded with the development of the peak left ventricular outflow gradient. Aortic flow after the notch was variable ranging from 6-48% of the total flow. In patients with pacemakers, improved response to pacing was noted in those patients that developed the notch early in systole and had subsequent attenuation of aortic flow. Optimizing the AVI was associated with improved exercise tolerance (AAI: 4.6 +/- 2.3 min., DDD30: 5.5 +/- 2.2 min., and DDDop: 7.7 +/- 2.5 min.; p < 0.05) and improved QOL.
CONCLUSIONS: Patients with HOCM have a notch in their aortic Doppler flow profile. The location of the notch correlates with the development of the peak left ventricular outflow gradient and flow after the notch is variable. Patients with an early notch and attenuated flow after the notch appear to have the greatest response to pacing therapy.

Entities:  

Mesh:

Year:  2004        PMID: 15273454     DOI: 10.1023/B:JICE.0000035929.84238.2f

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  18 in total

1.  Hypertrophic obstructive cardiomyopathy. Assessment by echocardiographic and Doppler ultrasound techniques.

Authors:  D R Boughner; R L Schuld; J A Persaud
Journal:  Br Heart J       Date:  1975-09

2.  Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy.

Authors:  S F Nagueh; S R Ommen; N M Lakkis; D Killip; W A Zoghbi; H V Schaff; G K Danielson; M A Quiñones; A J Tajik; W H Spencer
Journal:  J Am Coll Cardiol       Date:  2001-11-15       Impact factor: 24.094

3.  Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy.

Authors:  Waqar Shamim; Mohammed Yousufuddin; Duolao Wang; Michael Henein; Hubert Seggewiss; Marcus Flather; Andrew J S Coats; Ulrich Sigwart
Journal:  N Engl J Med       Date:  2002-10-24       Impact factor: 91.245

4.  Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy.

Authors:  A G MORROW; E C BROCKENBROUGH
Journal:  Ann Surg       Date:  1961-08       Impact factor: 12.969

5.  Unobstructed thinking (and terminology) is called for in the understanding and management of hypertrophic cardiomyopathy.

Authors:  J M Criley
Journal:  J Am Coll Cardiol       Date:  1997-03-15       Impact factor: 24.094

6.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

7.  Patterns and timing of Doppler-detected intracavitary and aortic flow in hypertrophic cardiomyopathy.

Authors:  P G Yock; L Hatle; R L Popp
Journal:  J Am Coll Cardiol       Date:  1986-11       Impact factor: 24.094

8.  Echocardiographic and Doppler flow observations in obstructed and nonobstructed hypertrophic cardiomyopathy.

Authors:  J M Gardin; A Dabestani; G A Glasgow; S Butman; C S Burn; W L Henry
Journal:  Am J Cardiol       Date:  1985-10-01       Impact factor: 2.778

9.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.

Authors:  U Sigwart
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

10.  Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.

Authors:  L Fananapazir; N D Epstein; R V Curiel; J A Panza; D Tripodi; D McAreavey
Journal:  Circulation       Date:  1994-12       Impact factor: 29.690

View more
  3 in total

Review 1.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Constantinos O'Mahony; Saidi A Mohiddin; Charles Knight
Journal:  Interv Cardiol       Date:  2014-04

3.  Right ventricular pacing for hypertrophic obstructive cardiomyopathy: meta-analysis and meta-regression of clinical trials.

Authors:  Ahran D Arnold; James P Howard; Kayla Chiew; William J Kerrigan; Felicity de Vere; Hannah T Johns; Leonid Churlilov; Yousif Ahmad; Daniel Keene; Matthew J Shun-Shin; Graham D Cole; Prapa Kanagaratnam; S M Afzal Sohaib; Amanda Varnava; Darrel P Francis; Zachary I Whinnett
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2019-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.